Vertex Pharmaceuticals Inc / Ma
—- Market cap
- $130.64B
- Debt
- —
- Cash
- −$5.08B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $130.64B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
Decision snapshot: VRTX stock price vs RTX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RTX's multiple
Needs RTX P/E.
Implied fair value · at VRTX's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
RTX CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
VRTX vs AMGN
Gilead Sciences, Inc.
VRTX vs GILD
BIOGEN INC.
VRTX vs BIIB
Moderna, Inc.
VRTX vs MRNA
Illumina, Inc.
VRTX vs ILMN
General Electric Company
VRTX vs GE
HONEYWELL INTERNATIONAL INC
VRTX vs HON
Parker-Hannifin Corp
VRTX vs PH
Spirit AeroSystems Holdings, Inc.
VRTX vs SPR
TransDigm Group INC
VRTX vs TDG
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe VRTX can sustain its premium profitability and capital efficiency while maintaining a valuation in line with RTX-based implied price, then the stock looks attractive because its current price is 27.4% below that estimate and its margins and ROIC are materially stronger than RTX.
On the provided P/E basis, VRTX's current price of $444.93 sits about 27.4% below the implied price of $566.87, suggesting meaningful upside if RTX-multiple framework holds. The valuation gap appears driven less by operating weakness and more by the market applying a lower multiple to VRTX despite materially stronger profitability and capital efficiency than RTX.
Supporting Metrics